Pharvaris NVNASDAQ:PHVS
- LAST PRICE20.2500
- TODAY'S CHANGE (%)-1.0000 (-4.7059%)
- Bid / Lots19.8900/ 1
- Ask / Lots20.4200/ 1
- Open / Previous Close20.7400 / 21.2500
- Day Range
- 52 Week Range
- Volume19,908
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PHVS |
|---|---|---|
| 09:32 ET | 995 | 20.0712 |
| 09:52 ET | 100 | 20.35 |
| 09:59 ET | 576 | 20.12 |
| 10:06 ET | 397 | 20.07 |
| 10:10 ET | 600 | 19.91 |
| 10:12 ET | 100 | 19.9267 |
| 10:14 ET | 500 | 19.89 |
| 10:15 ET | 400 | 19.7 |
| 10:19 ET | 1700 | 19.97 |
| 10:21 ET | 100 | 20.18 |
| 10:30 ET | 100 | 20.2 |
| 10:37 ET | 500 | 20.2101 |
| 10:39 ET | 807 | 20.28 |
| 10:42 ET | 100 | 20.425 |
| 11:00 ET | 100 | 20.3 |
| 11:42 ET | 992 | 19.875 |
| 11:44 ET | 200 | 20.12 |
| 11:56 ET | 100 | 19.96 |
| 12:00 ET | 100 | 20.35 |
| 12:12 ET | 800 | 19.9201 |
| 12:14 ET | 100 | 19.93 |
| 12:16 ET | 356 | 20 |
| 12:25 ET | 100 | 20 |
| 12:50 ET | 100 | 20.25 |
Apr 22, 2024
DJ Pharvaris Is Maintained at Overweight by Morgan Stanley, from 1:38PM ET on Monday Apr 22, 2024 by Dow Jones
1:38PM ET on Monday Apr 22, 2024 by Dow Jones
Apr 15, 2024
DJ Pharvaris Is Maintained at Overweight by Morgan Stanley, from 12:56PM ET on Monday Apr 15, 2024 by Dow Jones
12:56PM ET on Monday Apr 15, 2024 by Dow Jones
Apr 11, 2024
DJ Pharvaris Is Maintained at Market Outperform by JMP Securities, from 12:23PM ET on Thursday Apr 11, 2024 by Dow Jones
12:23PM ET on Thursday Apr 11, 2024 by Dow JonesDJ Pharvaris Price Target Maintained With a $35.00/Share by Wedbush, from 10:10AM ET on Thursday Apr 11, 2024 by Dow Jones
10:10AM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 10, 2024
DJ Pharvaris Taps David Nassif as Finance Chief, from 4:28PM ET on Wednesday Apr 10, 2024 by Dow Jones
4:28PM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pharvaris NV | 1.1B | -7.5x | --- |
Verona Pharma PLC | 1.2B | -22.3x | --- |
Spyre Therapeutics Inc | 1.2B | -0.4x | --- |
Soleno Therapeutics Inc | 1.3B | -12.9x | --- |
Autolus Therapeutics PLC | 1.1B | -3.4x | --- |
Day One Biopharmaceuticals Inc | 1.3B | -5.7x | --- |
Company Information
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Contact Information
- Headquarters
- J.H. Oortweg 21LEIDEN, Netherlands 2333 CH
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer, Co-Founder, Executive Director
- Berndt Modig
- Co-Founder, Chief Operating Officer, Chief Scientific Officer
- Jochen Knolle
- Co-Founder, Non-Executive Director
- Hans Schikan
- Co-Founder, Chief Early Development Officer
- Anne Lesage
- Chief Financial Officer
- David Nassif
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 53.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.70 |
Book Value | $7.86 |
P/E Ratio | -7.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
